Clinical data | |
---|---|
Trade names | Ixempra |
Other names | Azaepothilone B |
AHFS/Drugs.com | Monograph |
MedlinePlus | a608042 |
License data |
|
Routes of administration | Intravenous infusion |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | 67 to 77% |
Metabolism | Extensive, hepatic, CYP3A4-mediated |
Elimination half-life | 52 hours |
Excretion | Fecal (mostly) and renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.158.736 |
Chemical and physical data | |
Formula | C27H42N2O5S |
Molar mass | 506.70 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is a pharmaceutical drug developed by Bristol-Myers Squibb as a chemotherapeutic medication for cancer.[2]